AAN 2016 Multiple Sclerosis

Patients with active relapsing-remitting multiple sclerosis (MS) who had an inadequate response to one or more prior therapies at baseline showed durable improvement in clinical efficacy with alemtuzumab at 5 years.

A post-hoc analysis of pooled data from 2 clinical trials showed that teriflunomide use is associated with reduced disability progression after MS relapse, compared to placebo. The findings were presented at the 68th AAN Annual Meeting.

In a comparative study of disease modifying therapies (DMT) for multiple sclerosis (MS), delayed-release dimethyl fumarate (DMF) was shown to lower annualized relapse rates (ARR) more than other DMTs.

Early administration of subcutaneous interferon (sc IFN) β-1a is associated with better rates of no-evidence-of-disease-activity (NEDA) status than delayed treatment among patients with clinically isolated syndrome (CIS), according to a research-poster presentation at the 68th AAN Annual Meeting.

Disease-modifying treatments in relapsing-remitting multiple sclerosis (MS) showed similar effects in those whose disease onset was in childhood compared with adult onset.

Patients with relapsing-remitting multiple sclerosis (MS) treated with daclizumab high-yield process (HYP) had improved cognitive outcomes at 96 weeks compared with interferon-β-1a.

Arbaclofen extended release tablets (AERT) proved greater tolerability, and similar efficacy and safety, to baclofen in patients with multiple sclerosis (MS), according to randomized trial results reported at the 68th AAN Annual Meeting.

Delayed-release dimethyl fumarate (DMF) was associated with significant reductions in confirmed disability progression (CDP) in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS), compared with placebo.

Daclizumab high-yield process (DAC HYP) demonstrated greater efficacy, exclusive of acute relapse, than interferon (IFN) beta-1a in prolonging the onset of disability progression in relapsing-remitting multiple sclerosis (RRMS).

Teriflunomide treatment decreased brain volume loss in patients with relapsing-remitting multiple sclerosis (MS) independent of disability progression, a study presented at the 68th AAN Annual Meeting concluded.